Larvol Delta - Results-of-the-ADAPT-phase-3-study-of-RocapuldencelT-in-combination-with-sunitinib-as-rstline-therapy-in-patients-with-metastatic-renal-cell-carcinoma

rocapuldencel-T (CMN-001) - CoImmune

Sutent (sunitinib) - Pfizer

http://www.ncbi.nlm.nih.gov/pubmed/32034074

Feb 10, 2020

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next